In the pharmaceutical industry, quality, safety and regulatory compliance are part of everyday business.
Yet there is one area that continues to challenge even the most experienced professionals: pharmaceutical taxes and sector-specific contributions.
A highly technical, constantly evolving and often opaque landscape—yet one that remains essential for every pharmaceutical company.
1. A Tax System That Is Far More Complex Than It Appears
Pharmaceutical companies are subject to a wide range of taxes and contributions that have accumulated over time, including:
- Turnover-based contributions,
- Additional sector-specific contributions,
- Regulatory exemptions,
- Corrective mechanisms,
- Transitional arrangements.
Beyond turnover-based contributions, several other obligations further complicate the reporting landscape, including:
- Promotional taxes,
- Contributions on direct sales to community pharmacies,
- The safeguard clause (and its various mechanisms),
- Volume- and price-related adjustment schemes,
- Specific regimes applicable to certain products or distribution channels.
Each contribution has its own calculation basis, rates, exemptions and eligibility criteria.
Understanding this framework can quickly become a significant challenge without dedicated regulatory or tax expertise.
Yet Responsible Pharmacists and regulatory teams are often expected to understand its implications without always having the necessary resources.
Adding to the complexity, the French Social Security Financing Act (LFSS) is updated every year, meaning that regulatory requirements may change from one year to the next.
What was applicable yesterday may no longer apply tomorrow.
2. A Challenging Timeline: Declaring Today, Paying Much Later
Another source of complexity lies in the timing of declarations and payments.
Data relating to a given year are often declared several months later.
The corresponding amounts due are calculated and communicated even later.
Actual payment may occur more than a year after the period concerned.
By then, teams may have changed, product portfolios may have evolved and sales volumes may differ significantly, making it increasingly difficult to understand exactly what is being paid—and why.
3. Questions Almost Every Pharmaceutical Company Asks
Many companies face the same questions:
- Are we actually subject to a particular contribution?
- Have we correctly identified all applicable exemptions?
- How can we anticipate future contributions and avoid unexpected costs?
- How should these contributions be integrated into financial planning?
- How can we keep pace with legislative changes without dedicating significant internal resources?
These questions arise regardless of company size.
And understandably so: the system was never designed to be intuitive.
4. Our Role: Bringing Clarity to Complexity
This is precisely where ATESSIA supports pharmaceutical companies by helping them:
- Clearly identify the contributions applicable to their activities,
- Determine whether they are subject to each regulatory mechanism,
- Assess relevant exemptions (orphan medicines, early access, compassionate use, generics, hybrids, biosimilars and mature products),
- Estimate future financial liabilities,
- Secure regulatory declarations,
- Monitor regulatory developments from one year to the next.
Our objective is not to turn operational teams into tax specialists, but to provide them with the visibility they need to make informed decisions with confidence.
Conclusion: A Technical Topic with Strategic Impact
Pharmaceutical taxes and contributions have a significant impact on cash flow, regulatory compliance, business strategy and, in some cases, commercial decision-making.
In such a complex regulatory environment, expert support can make all the difference.
If you would like to gain a clearer understanding of your obligations—or simply confirm that your current approach is the right one—we would be pleased to discuss your needs.
Article written by Raphaël DAUVERGNE, Legal Consultant specializing in Health Law